Bioterrorism Defense Bill Could Change Patent Law

Law360, New York (October 18, 2005, 12:00 AM EDT) -- In its bid to protect the U.S. from biological terrorism, Capitol Hill is sparking a battle between the pharmaceutical industry and its generics rivals over new patent and market exclusivity in the name of national defense.

The new version of the controversial National Biodefense Act of 2005, dubbed “BioShield II,” was the subject of an executive session Tuesday before the Senate Judiciary Subcommittee on Health, Education, Labor and Pensions (HELP). The current draft will provide valuable incentives to the drug industry to spur development of defensive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.